Alzheimer’s Drug on the Works for Roche

Recommend to others!

Roche Holding AG, more popularly known as Roche, is currently developing an experimental drug which targets to treat Alzheimer’s Disease among the elderly. According to the Swiss drugmaker on Sunday, this certain drug is targeted to remove the amyloid plaques in the brains of patients with Alzheimer’s Disease of an early stage.

Most researchers and experts believe that the cause of this memory robbing disease is the formation of these amyloid plaques—however this theory has not been very conclusive yet and further studies are aimed in determining the said cause.

The next step of the study will be towards investigating as to whether removing these amyloid plaques will lead to benefits for the patients with Alzheimer’s. The potential drug is called Gantenerumab and is expected to be well tolerated and safe for people with AD. Gantenerumab is a biotech drug which is designed to cling into amyloid plaques in the brain and remove them. It is being targeted to slow the progression of the said disease, during its early stage when the patients are still able to make use of their brain functions efficiently and effectively.

During the first phase of the study, researchers tested the said drug in 16 patients with Alzheimer’s in two doses against patients who are receiving placebo drug. The said drug paved the way to a dose-dependent reduction of the plaques, while on the other hand, among those receiving placebo medications, showed an increase in the presence of amyloid plaques.

According to the researchers, larger studies need to be carried out in order to make sure as to how gantenerumab really works and whether this drug can prevent the progression of Alzheimer’s Disease.

“These results and especially the rapidity of the effects observed on amyloid removal are very encouraging and pave the way for the development of a novel treatment for Alzheimer’s disease,” said Luca Santarelli who is the head of the Global Neuroscience Disease Division. While most companies targeting to create treatments for Alzheimer’s Disease in its later stage, Roche plans to the approach the disease at an earlier stage.

According to the Alzheimer’s Association, Alzheimer’s is the most common form of dementia, a general term for memory loss and other intellectual abilities serious enough to interfere with daily life. Alzheimer’s disease accounts for 50 to 80 percent of dementia cases.

Alzheimer’s worsens over time. Alzheimer’s is a progressive disease, where dementia symptoms gradually worsen over a number of years. In its early stages, memory loss is mild, but with late-stage Alzheimer’s, individuals lose the ability to carry on a conversation and respond to their environment. Alzheimer’s is the sixth leading cause of death in the United States. Those with Alzheimer’s live an average of eight years after their symptoms become noticeable to others, but survival can range from four to 20 years, depending on age and other health conditions.

Comments

comments

Comments

  1. This is great news for early onset AD. For all patients there are options available. As we look at the treatment options for Alzheimer’s Disease let us keep an open mind as to all options available. There is not a known cure for Alzheimer’s as yet. We hope to see this sometime, hopefully not far down the road. In the meantime the use of pharmaceutical medications have at least helped Alzheimer’s patients to have some success. There are also natural supplements which-with the use of the pharmaceuticals-may take things a step further. Many people who have participated in medical research have seen significant changes. In as little as 24 months people have been able to go back to some form of occupations. So many of us are not aware of this because unless someone pays to have this heard it is kept under a rock. God Bless those who take that extra step to look a little deeper. Most of us are too devastated to do so and need help from those who keep an open mind.
    http://bit.ly/n8HWKX

Speak Your Mind

*

Current day month ye@r *